The immunological landscape of metabolic dysfunction-associated steatohepatitis (MASH)-driven hepatocellular carcinoma (HCC) is not well understood.
Herein, we aim to delineate the immunological landscape in the MASH-to-HCC transition and to identify the critical genes that contribute to the pathogenesis of MASH-related HCC.
